The new major version with a new JIT compiler, a revised parallelization API, and a maturing type system paves the way for ...

If you work with strings in your Python scripts and you're writing obscure logic to process them, then you need to look into ...

A large alligator nicknamed 'Godzilla' was caught on video dragging an enormous Burmese python through the water in the Florida Everglades.

Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

In October 1984 I arrived at Oxford University, trailing a large steamer trunk containing a couple of changes of clothing and about five dozen textbooks. I had a freshly minted bachelor’s degree in ...

Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...

Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...

Michigan bluegrass phenom Billy Strings and his band stopped by NPR’s Tiny Desk for a performance more than a decade in the making. Backed by his band — Alex Hargreaves on fiddle, backing vocalist ...

DNA Ginkgo Bioworks Holdings, Inc.